Follicular-Phase GnRH Agonist Protocol Is Another Choice for Polycystic Ovary Syndrome Patients With Lower LH/FSH and Lower AMH Levels Without Increasing Severe OHSS Risk.

Front Endocrinol (Lausanne) · 2022 · PMC9232123 · PMID 35757417

Europe PMC DOI

hedged sentence

0.4500

closest p · 9.0× alpha

0.4500

boldest claim

The sentences

did not reach statistical significancep = 0.45not close (p > 0.1)

64.3%), but this difference did not reach statistical significance [OR (95% CI): 0.67 (0.24–1.92) and 0.51 (0.08–3.49); p = 0.45 and 0.49].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.